Daniel J Sexton

This inventor holds 43 USPTO granted patents and 26 published patent applications, plus 10 CIPO patents and 22 EPO patents, primarily in Biomarker Discovery. Top assignees: Takeda Pharmaceutical Company Limited, Dyax Corporation, Bracco Suisse Sa. Active years: 2008-2025.

USPTO Granted Patents = 43 (Patent Applications = 26)

% Patents Active = 97.7

CIPO Patents = 10 (Patent Applications = 13)

EPO Patents = 22 (Patent Applications = 33)

Average Co-Inventor Count = 3.2

ph-index = 8

Forward Citations = 242(Granted Patents)

Company Filing History:

23 out of 1,222

Takeda Pharmaceutical Company Limited

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Biomarkers

Plasma Kallikrein

Autoimmune Diseases

FcRn-Binding Antibodies

Kininogen

Hereditary Angioedema

Diabetic Macular Edema

Immunoassays

Peptide Quantitation

Protein Biomarkers

Monoclonal Antibodies

Nucleic Acids

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12493047 - CLEAVED HIGH MOLECULE WEIGHT KININOGEN (HMWK) ANTIBODIES AND METHODS OF USING (2025-12-09),

2. 12460016 - Plasma kallikrein binding proteins (2025-11-04),

3. 12454575 - Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies (2025-10-28),

4. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

5. 12415866 - Monoclonal antibody inhibitor of Factor XIIa (2025-09-16),

6. 12384854 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2025-08-12),

7. 12188948 - Metabolite biomarkers for diseases associated with the contact activation system (2025-01-07),

8. 12135329 - Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK (2024-11-05),

9. 12084515 - Compositions and methods for treatment of diabetic macular edema (2024-09-10),

10. 12061206 - Diagnosis and treatment of autoimmune diseases (2024-08-13),

11. 11884979 - RNA biomarkers for hereditary angioedema (2024-01-30),

12. 11826758 - Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation (2023-11-28),

13. 11815516 - Protein biomarkers for diseases associated with the contact activation system (2023-11-14),

14. 11739152 - Antibodies which bind Fc receptors (FcRn) (2023-08-29),

15. 11668718 - Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK (2023-06-06),

Title: Daniel J Sexton - Innovative Inventor from Melrose, MA

Introduction: Daniel J Sexton is a renowned inventor hailing from Melrose, MA, known for his groundbreaking contributions to various fields.

Latest Patents: Daniel J Sexton holds several patents in the areas of technology and healthcare, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a career spanning over two decades, Daniel J Sexton has worked tirelessly to bring his inventions to life, revolutionizing industries and improving the lives of many.

Collaborations: Throughout his career, Daniel J Sexton has collaborated with leading companies, research institutions, and universities to further develop and implement his innovative ideas, solidifying his reputation as a visionary inventor.

Conclusion: Daniel J Sexton's passion for innovation and his relentless drive to push boundaries have cemented his legacy as a pioneering inventor in the world of technology and beyond.